Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival | NCT07731425

NCT07731425

Overview

NCT ID: NCT07731425
Lead Sponsor: London School of Economics and Political ScienceOTHER
Official Title: Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival: a Randomized Controlled Trial
Brief Summary: This study of current or former cancer patients will evaluate whether communicating data on overall survival data in addition to information on progression-free improves the accuracy of cancer patients' expectations about the survival benefits of new cancer drugs
Conditions: Cancer
Interventions: FDA explanation for progression-free survival (control)

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

US adults with a current or former cancer diagnosis (excluding nonmelanoma skin cancer)

US adults 18 years of age and older, fluent in English, and residing in the United States.

Exclusion Criteria:

Adults who do not have a former cancer diagnosis or who were diagnosed with nonmelanoma skin cancer; adults who complete the survey in under 150 seconds, and who do not meet the other inclusion criteria.

Central Contacts: Avi CherlaContact
avi_cherla@hphci.harvard.edu020 7955 7975

Participant Group/Arms

FDA explanation for progression-free survival (control)Placebo Comparator

Other: FDA explanation for progression-free survival (control)

FDA explanation for progression-free survival with overall survival dataExperimental

Other: FDA explanation for progression-free survival with overall survival data

NCI explanation for progression-free survivalExperimental

Other: NCI explanation for progression-free survival

NCI explanation for progression-free survival with overall survival dataExperimental

Other: NCI explanation for progression-free survival with overall survival data

Plain-language explanation of progression-free survivalExperimental

Other: Plain-language explanation of progression-free survival

Plain-language explanation of progression-free survival with overall survival dataExperimental

Other: Plain-language explanation of progression-free survival with overall survival data